The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death.

摘要: Forty years ago, the endocrine treatment for breast cancer was a last resort at palliation before disease overwhelmed patient (1). Ovarian ablation of choice premenopausal patient, whereas either adrenalectomy or, paradoxically, high-dose synthetic estrogen therapy were used in postmenopausal patients. A reduction or an excess provoked objective responses one out three women. Unfortunately, there no way predicting who would respond to ablation, and because so few patients responded enthusiasm developing new agents. All hopes cure turned appropriate combinations cytotoxic chemotherapy. Today tamoxifen, nonsteroidal antiestrogen (2), has proven be effective all stages cancer, several strategies, including aromatase inhibitors, luteinizing-hormone releasing hormone (LHRH) superagonists, pure (fulvestrant), are now available treatment. Additionally, tamoxifen raloxifene, related compound, reduce risk osteoporosis, respectively, high-risk groups (3). Hormonal modulation strategies prevent actions ubiquitous. However, with successful changes comes consequence change. This minireview will describe current prevention present emerging concepts about consequences exhaustive on therapeutic resistance.